Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography.

Kim H, Chung WB, Cho KI, Kim BJ, Seo JS, Park SM, Kim HJ, Lee JH, Kim EK, Youn HJ.

J Cardiovasc Ultrasound. 2018 Mar;26(1):1-25. doi: 10.4250/jcu.2018.26.1.1. Epub 2018 Mar 28. Review.

2.

Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.

Kim MS, Lee JH, Kim EJ, Park DG, Park SJ, Park JJ, Shin MS, Yoo BS, Youn JC, Lee SE, Ihm SH, Jang SY, Jo SH, Cho JY, Cho HJ, Choi S, Choi JO, Han SW, Hwang KK, Jeon ES, Cho MC, Chae SC, Choi DJ.

Korean Circ J. 2017 Sep;47(5):555-643. doi: 10.4070/kcj.2017.0009. Epub 2017 Sep 18. Review.

3.

Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy.

Yeo W, Mo FKF, Pang E, Suen JJS, Koh J, Loong HHF, Yip CCH, Ng RYW, Yip CHW, Tang NLS, Liem GS.

BMC Womens Health. 2017 Jul 27;17(1):55. doi: 10.1186/s12905-017-0409-8.

4.

Tyrosine kinase-targeting drugs-associated heart failure.

Gronich N, Lavi I, Barnett-Griness O, Saliba W, Abernethy DR, Rennert G.

Br J Cancer. 2017 May 9;116(10):1366-1373. doi: 10.1038/bjc.2017.88. Epub 2017 Apr 11.

PMID:
28399109
5.

Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance.

Huang H, Nijjar PS, Misialek JR, Blaes A, Derrico NP, Kazmirczak F, Klem I, Farzaneh-Far A, Shenoy C.

J Cardiovasc Magn Reson. 2017 Mar 24;19(1):34. doi: 10.1186/s12968-017-0348-4.

6.

Cardiotoxicity Following Cancer Treatment.

Walls GM, Lyon AR, Harbinson MT, Hanna GG.

Ulster Med J. 2017 Jan;86(1):3-9. Review.

7.

Trastuzumab-associated cardiac events in the Persephone trial.

Earl HM, Vallier AL, Dunn J, Loi S, Ogburn E, McAdam K, Hughes-Davies L, Harnett A, Abraham J, Wardley A, Cameron DA, Miles D, Gounaris I, Plummer C, Hiller L.

Br J Cancer. 2016 Dec 6;115(12):1462-1470. doi: 10.1038/bjc.2016.357. Epub 2016 Nov 22.

8.

Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.

Davis CC, Zelnak A, Eley JW, Goldstein DA, Switchenko JM, McKibbin T.

Ann Pharmacother. 2016 Sep;50(9):712-7. doi: 10.1177/1060028016654160. Epub 2016 Jun 15.

9.

Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.

Kristeleit H, Parton M, Beresford M, Macpherson IR, Sharma R, Lazarus L, Kelleher M.

Target Oncol. 2016 Oct;11(5):579-591. Review.

10.

Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword.

Liu KL, Chen JS, Chen SC, Chu PH.

Acta Cardiol Sin. 2013 Jul;29(4):295-303. Review.

11.

Cardio-oncology: Concepts and practice.

Cubbon RM, Lyon AR.

Indian Heart J. 2016 Apr;68 Suppl 1:S77-85. doi: 10.1016/j.ihj.2016.01.022. Epub 2016 Feb 11. Review.

12.

Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis.

Long HD, Lin YE, Zhang JJ, Zhong WZ, Zheng RN.

Oncologist. 2016 May;21(5):547-54. doi: 10.1634/theoncologist.2015-0424. Epub 2016 Mar 29.

13.

Risk factors for anthracycline-associated cardiotoxicity.

Reinbolt RE, Patel R, Pan X, Timmers CD, Pilarski R, Shapiro CL, Lustberg MB.

Support Care Cancer. 2016 May;24(5):2173-2180. doi: 10.1007/s00520-015-3008-y. Epub 2015 Nov 12.

14.

Clinical Experience of Patients Referred to a Multidisciplinary Cardiac Oncology Clinic: An Observational Study.

Sulpher J, Mathur S, Graham N, Crawley F, Turek M, Johnson C, Stadnick E, Law A, Wentzell J, Dent S.

J Oncol. 2015;2015:671232. doi: 10.1155/2015/671232. Epub 2015 Aug 2.

15.

Right ventricle failure associated wıth trastuzumab.

Bayar N, Küçükseymen S, Göktaş S, Arslan Ş.

Ther Adv Drug Saf. 2015 Jun;6(3):98-102. doi: 10.1177/2042098615582162.

16.

Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer.

Chavez-MacGregor M, Niu J, Zhang N, Elting LS, Smith BD, Banchs J, Hortobagyi GN, Giordano SH.

J Clin Oncol. 2015 Jul 1;33(19):2176-83. doi: 10.1200/JCO.2014.58.9465. Epub 2015 May 11.

17.

Cardiac safety of (neo)adjuvant trastuzumab in the community setting: a single-center experience.

da Fonseca LG, de Melo Gagliato D, Takahashi TK, Mak MP, Barroso-Sousa R, Testa L, Helena VP, de Paula Costa R, Hoff PM, Mano MS.

Breast Care (Basel). 2014 Apr;9(4):255-60. doi: 10.1159/000365950.

18.

Echocardiographic signs of right ventricle changes after Trastuzumab treatment in breast cancer patients with erb-2 overexpression.

Kılıçaslan B, Özdoğan Ö, Demir Pişkin G, Kahya Eren N, Dursun H.

Anatol J Cardiol. 2015 Feb;15(2):143-8. doi: 10.5152/akd.2014.5220. Epub 2014 Apr 2.

19.

Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.

Ezaz G, Long JB, Gross CP, Chen J.

J Am Heart Assoc. 2014 Feb 28;3(1):e000472. doi: 10.1161/JAHA.113.000472.

20.

Neuregulin as a heart failure therapy and mediator of reverse remodeling.

Galindo CL, Ryzhov S, Sawyer DB.

Curr Heart Fail Rep. 2014 Mar;11(1):40-9. Review.

Supplemental Content

Support Center